HCV Genofibro Test

The HCV Genofibro test provides a comprehensive assessment of HCV infection, including liver fibrosis/cirrhosis evaluation, genotyping, and IL28B genotype determination.

• To diagnose and confirm the presence of the Hepatitis C virus in your blood
• To evaluate the severity of the infection and identify the genotype, which helps determine the best course of treatment

Doctors recommend HCV Genofibro test if you have the symptoms or risk factors for Hepatitis C virus infection. You will be advised to take the test if you have

• shared needles or drug equipment,
• received blood transfusion before 1992,
• been on long-term dialysis,
• been exposed to infected needles,
• been born to a mother with Hepatitis C,
• had unprotected sex with an infected partner, or
• HIV.

An abnormal result indicates that you have Hepatitis C virus infection. The result may also indicate which genotype of the virus you have, which helps identify the best course of treatment.

The HCV Genofibro test requires a small blood sample drawn from your arm. The blood sample is sent to the laboratory for testing.

Inform your doctor about any medications, herbs, or supplements you are taking as these may affect your test results. Also, tell them if you have any specific requirements. Avoid alcohol consumption for at least 24 hours before the test.

• Liver function tests: These tests measure the levels of liver enzymes, proteins, and bilirubin in your blood to assess liver function and damage.
• HCV RNA Test: This test measures the amount of Hepatitis C virus in your blood to determine how much the virus has replicated and to monitor treatment effectiveness.

Hepatitis C virus genotyping and IL28B testing

Hepatitis C is a liver infection caused by the Hepatitis C Virus (HCV). The virus spreads through contaminated blood and can cause both acute and chronic hepatitis. Chronic hepatitis C infection can lead to serious liver damage, liver failure or liver cancer.

Fibromax is a non-invasive diagnostic tool that assesses liver fibrosis and cirrhosis. It combines several biomarkers, such as liver enzymes, platelet count, and other blood markers, to estimate the degree of liver damage caused by HCV infection.

HCV Genotyping determines the specific genotype of the HCV infection. Genotyping helps identify the genetic variations of the virus, which can guide treatment decisions. Different genotypes of HCV may respond differently to antiviral medications, and knowing the genotype helps in selecting the most appropriate treatment regimen.

The IL28B gene is involved in the immune response to HCV infection and can influence treatment outcomes. Certain genetic variations in the IL28B gene are associated with different response rates to antiviral therapy. Testing for IL28B genotype helps predict the likelihood of treatment success and may aid in tailoring the treatment plan.